These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 20379736)

  • 1. Elevated vascular endothelial growth factor level in Coats' disease and possible therapeutic role of bevacizumab.
    He YG; Wang H; Zhao B; Lee J; Bahl D; McCluskey J
    Graefes Arch Clin Exp Ophthalmol; 2010 Oct; 248(10):1519-21. PubMed ID: 20379736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction.
    Ramasubramanian A; Shields CL
    Br J Ophthalmol; 2012 Mar; 96(3):356-9. PubMed ID: 21653215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal anti-vascular endothelial growth factor agents as an adjunct in the management of Coats' disease in children.
    Kaul S; Uparkar M; Mody K; Walinjkar J; Kothari M; Natarajan S
    Indian J Ophthalmol; 2010; 58(1):76-8. PubMed ID: 20029154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resolution of macular edema in Coats' disease with intravitreal bevacizumab.
    Entezari M; Ramezani A; Safavizadeh L; Bassirnia N
    Indian J Ophthalmol; 2010; 58(1):80-2. PubMed ID: 20029156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resolution of severe macular edema in adult coats' disease with intravitreal triamcinolone and bevacizumab injection.
    Jun JH; Kim YC; Kim KS
    Korean J Ophthalmol; 2008 Sep; 22(3):190-3. PubMed ID: 18784449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Coats disease with bevacizumab in 2 patients.
    Venkatesh P; Mandal S; Garg S
    Can J Ophthalmol; 2008 Apr; 43(2):245-6. PubMed ID: 18347637
    [No Abstract]   [Full Text] [Related]  

  • 7. Vascular endothelial growth factor in Coats' disease.
    Zhao Q; Peng XY; Chen FH; Zhang YP; Wang L; You QS; Jonas JB
    Acta Ophthalmol; 2014 May; 92(3):e225-8. PubMed ID: 23764089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of intravitreal bevacizumab injection as the initial treatment for Coats' disease.
    Zheng XX; Jiang YR
    Graefes Arch Clin Exp Ophthalmol; 2014 Jan; 252(1):35-42. PubMed ID: 23873253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coats' disease: treatment with intravitreal bevacizumab and laser photocoagulation.
    Stergiou PK; Symeonidis C; Dimitrakos SA
    Acta Ophthalmol; 2009 Sep; 87(6):687-8. PubMed ID: 18976310
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful use of intravitreal bevacizumab and pascal laser photocoagulation in the management of adult Coats' disease.
    Raoof N; Quhill F
    Middle East Afr J Ophthalmol; 2013; 20(3):256-8. PubMed ID: 24014992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium.
    Sun Y; Jain A; Moshfeghi DM
    Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1387-8. PubMed ID: 17342503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined intravitreal bevacizumab and argon laser treatment for Coats' disease.
    Cackett P; Wong D; Cheung CM
    Acta Ophthalmol; 2010 Mar; 88(2):e48-9. PubMed ID: 19500078
    [No Abstract]   [Full Text] [Related]  

  • 13. Intravitreal bevacizumab therapy for idiopathic macular telangiectasia.
    Matsumoto Y; Yuzawa M
    Jpn J Ophthalmol; 2010 Jul; 54(4):320-4. PubMed ID: 20700800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination treatment of pediatric coats' disease: a bicenter study in Taiwan.
    Lin CJ; Chen SN; Hwang JF; Yang CM
    J Pediatr Ophthalmol Strabismus; 2013; 50(6):356-62. PubMed ID: 24669373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of intravitreal bevacizumab in the treatment of Coats disease in children.
    Lin CJ; Hwang JF; Chen YT; Chen SN
    Retina; 2010 Apr; 30(4):617-22. PubMed ID: 19996822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy.
    Sawada O; Kawamura H; Kakinoki M; Sawada T; Ohji M
    Arch Ophthalmol; 2007 Oct; 125(10):1363-6. PubMed ID: 17923544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1.
    Sohn EH; He S; Kim LA; Salehi-Had H; Javaheri M; Spee C; Dustin L; Hinton DR; Eliott D
    Arch Ophthalmol; 2012 Sep; 130(9):1127-34. PubMed ID: 22965588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Tractional Retinal Detachment Following Intravitreal Bevacizumab Along with Subretinal Fluid Drainage and Cryotherapy for Stage 3B Coats' Disease.
    Bhat V; D'Souza P; Shah PK; Narendran V
    Middle East Afr J Ophthalmol; 2016; 23(2):208-11. PubMed ID: 27162454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab.
    Nonobe NI; Kachi S; Kondo M; Takai Y; Takemoto K; Nakayama A; Hayakawa M; Terasaki H
    Retina; 2009 May; 29(5):579-85. PubMed ID: 19430279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased nitric oxide and vascular endothelial growth factor levels in the aqueous humor of patients with coats' disease.
    Zhang H; Liu ZL
    J Ocul Pharmacol Ther; 2012 Aug; 28(4):397-401. PubMed ID: 22233441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.